Pharmatrain

Pharmaceutical Medicine Training Programme
Ongoing | IMI1 |
Pharmaceutical Medicine Training Programme

FACTS & FIGURES

Start Date
End Date
Call
IMI1 - Call 1
Grant agreement number
115013

Contributions
IMI Funding
3 510 300
EFPIA in kind
3 489 181
Other
529 606
Total Cost7 529 087

Summary

The main objective of the PharmaTrain project is to build and implement a new modular Master level programme for advanced studies in Pharmaceutical Medicine and Drug Development Sciences. The programme is based on the Bologna credit and title system and builds on the new PharmaTrain Syllabus 2010 of the European Federation of Courses in Pharmaceutical Medicine (EFCPM).

The modular concept of the training programme also provides an opportunity to professionals to select courses for accredited Continuing Professional Development (CPD), as well as individualised training à la carte.  The PharmaTrain consortium has identified 6 base courses and 13 master level programmes at European universities that will be standardised at the same quality level. PharmaTrain will set, maintain and constantly improve the standards and quality management of the training schemes and practices for pharmaceutical professionals

The programme will encourage exchanges between the industry, regulators and academia, produce and promote distance e-learning programmes, and will enable increased flexibility, transferability and mobility. By providing a chart of available and planned training programmes at the different levels across Europe, PharmaTrain will identify the regions with the greatest needs. A uniform high-level training in Europe will make the drug development process faster, more economical, more tailored to patients’ needs, and will give Europe a global advantage in developing new innovative medicines. PharmaTrain is a collaboration of 20 EFCPM university training programmes, 13 learned societies including 3 competent authorities, several partner training organizations and 15 pharmaceutical companies. One year after its start, May 1, 2009, PharmaTrain has gained full momentum and has met basically all milestone deliverables in the ‘Prepare Phase’ and now launches the next two years of the Learn/Execution Phase.

First year results include:

  • creation of new postgraduate training curricula with syllabus standardised modularisation and related learning outcomes providing increased mobility
  • unified examination principles
  • different mixes of blended e-learning for comparative testing during the programme
  • combined with a new concept of cooperative training among new EU member states as well as a pan-European accreditation system
  • a continuing Professional Development (CPD) Platform and a comprehensive quality management process

Achievements & News

Cooperative European Medicines Development Course – registration open!
July 2015 - Registration is now open for the third edition of the Cooperative European Medicines Development Course (CEMDC) course which will kick off in September this year. The course, which was designed under the IMI project PharmaTrain, aims to educate experts in the process of medicines development ###and train them to apply this knowledge in large or small, innovative or generic pharmaceutical companies, regulatory agencies, healthcare and health research or insurance management. The course material was carefully compiled by academic and industry experts to meet the needs of both the pharmaceutical industry and health care and covers the following areas:
 - drug development and clinical trials;
 - regulatory affairs and safety of medicines;
 - life cycle management and medical marketing of medicines;
 - healthcare and professionalism.
The teaching follows the international, harmonized modular training programme and quality standards developed by PharmaTrain. The CEMDC is Coordinated by the Semmelweis University in Hungary and is accredited as a PharmaTrain Center of Excellence. The Diploma Course contains 8 modules, and students can opt to follow selected modules only or the entire course.
 - Deadline for registration: 31 August 2015
 -
Details of how to register can be found on the CEMDC website

Join PharmaTrain in Rome
May 2015 - PharmaTrain has teamed up with the International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical medicine (IFAPP) and the Società de Scienze Farmacologiche Applicate (SSFA) to organise a joint event in Rome, Italy on 10-11 June 2015. The event, ‘Advancing competent professionals in medicines development’, will present the results of the IMI project PharmaTrain. ###Over the past five years, Pharmatrain has put together a new concept for education in pharmaceutical medicine. Another highlight of the event will be the presentation of a complementary and new personal development programme which will lead to the title of SMD – ‘Specialist in Medicines Development’. The SMD project, a global initiative, will be soon implemented in Italy, Japan and in many more countries.
- Find out more

PharmaTrain Cooperative European Medicines Development Course: applications open
December 2014 - Applications are now open for the Cooperative European Medicines Development Course (CEMDC), a postgraduate course designed through IMI’s PharmaTrain. ###The aim of the course is to train experts who understand the complex process of medicines development from molecule to healthcare and who can apply this knowledge working in large or small companies, regulatory agencies, in health care and health insurance management. The course consists of a basic course of six modules which provide a complete overview of all drug development related topics listed in the Pharmatrain Syllabus. Combined with six further advanced elective modules and followed by a thesis based on scientific work, students will work towards a Masters-level degree in Medicines Development. The course material was carefully compiled by academic and industry experts to meet the needs of both the pharmaceutical industry and health care and covers three main areas: drug development and clinical trials; regulatory affairs and safety of medicines; health care and professionalism. The joint course is offered by 10 cooperating regional universities and is coordinated by the Semmelweis University, Budapest, Hungary.
- The course will begin in the first half of 2015
- Deadline for applications: 31 January 2015
- Further information about the course is available on the CEMDC website

Meet the IMI Education and Training Programmes
December 2013 - There are five projects within IMI’s research training platform aiming to revolutionise education and training to deliver more effective and safe new medicines for patients – EMTRAIN, Eu2P, EUPATI, PharmaTrain, and SafeSciMET. Collaboration is the key to ###success and equally important is the projects' ability to reach intended audiences with information to raise awareness and encourage people to get involved in project activities. 
Over the next six months these projects will be represented at a variety of European and international conferences through display booths, dedicated sessions or individual presentations. If you are planning to attend any of the following events, please take the opportunity to stop by and find out what is happening in the IMI training and education programmes and how you can benefit, either from a professional or personal perspective. 
   - DIA EuroMeeting 2014  (Vienna, 25-27 March)
   - EUPATI Regional Meeting 2014  (Warsaw, 2-3 April)
   - World Research and Innovation Congress (Amsterdam, 5-6 June)
   - Euroscience Open Forum (Copenhagen, 21-26 June)

PharmaTrain forms partnership with ACRES
October 2013 - IMI’s Education and Training project PharmaTrain and the Alliance for Clinical Research Excellence and Safety (ACRES), an international not-for-profit organisation for setting global clinical trial site standards ###(including improving education and training of professionals in medicines development), have joined forces in a Strategic Alliance. The goal is to promote the adoption of new and reliable global standards for high-quality postgraduate education and training for individuals pursuing careers in the discovery, development, regulation and marketing of new medicines.
Proposed projects within the framework of the Strategic Alliance include the development and dissemination of curriculum standards for educational programs and the implementation of a global quality assessment and recognition process for educational programmes and training courses as part of the shared infrastructure necessary for the multi-stakeholder integration of education in medicines development.
PharmaTrain has developed a rigorous approach to standards-based education and training achieved through the creation of a Syllabus of Medicines Development, which is aligned with the core competencies for scientists involved in medicines development. This approach will be disseminated and implemented worldwide through the alliance with ACRES. ‘Currently over 30 leading universities in Europe and North America have implemented the PharmaTrain curriculum - with ACRES, our new strategic partner, we intend to offer PharmaTrain to the world', comments PharmaTrain coordinator Dr Ingrid Klingmann of the European Forum on Good Clinical Practice (EFGCP).
   - Read the full press release


PharmaTrain adds two universities to Centres of Excellence network
September 2013 - IMI’s Education and Training project PharmaTrain has added two universities to its Centres of Excellence network. The addition of Cardiff University and the Catholic University Medical School of Rome to the network brings ###the number of PharmaTrain Centres of Excellence to 11. Both universities are part of the PharmaTrain Global 45 Universities Network.
The programme within PharmaTrain’s framework at the Cardiff University is a Postgraduate Course in Pharmaceutical Medicine . ‘Excellent course content, experienced presenters and interaction with my colleagues from different medical specialties added immensely to my on-the-job training! […]. The Cardiff course equipped me with many ideas, which I will implement in my daily job,’ comments Dr Victoria Zazulina of Boehringer Ingelheim, UK.
The Catholic University of Rome offers a Master in Preclinical and Clinical Research and Development of Drugs. ‘The Course helped me to have a comprehensive look at different areas of clinical research. […] It has been an extremely rewarding experience, which I think will be an asset for my future career path,’ explains student Chiara Mozzetta.
   - Learn more about PharmaTrain’s upcoming courses

BIOVISION and the IMI Education & Training projects
February 2013 - IMI and the IMI Education & Training projects participated in BIOVISION - the World Life Sciences Forum, which was held in Lyon, France, on March 24-26 2013. It is the place where key stakeholders ###debate the impact of the latest scientific advances on society and share their vision on how to overcome health, environment and nutrition challenges. IMI Executive Director Michel Goldman participated in the plenary session ‘How to make better use of collective intelligence’. Mike Hardman, project coordinator of EMTRAIN, represented IMI and the IMI E&T projects in the BIOVISION Investor Conference workshop. Moreover, the IMI E&T projects organised a satellite event on ‘Training and Education in Europe’ where they  presented their activities to the forum’s participants at a booth in the exhibition area.

IMI Education & Training projects in the spotlight at DIA EuroMeeting 2013
February 2013 - This year’s DIA EuroMeeting, which was held in Amsterdam, the Netherlands from 4 to 6 March, featured an entire theme dedicated to IMI’s five Education & Training (E&T) projects. The sessions featured ###the latest news from the projects and demonstrated how they are helping to advance education in the biomedical sector in Europe. DIA EuroMeeting visitors could also catch up with the projects and find out how IMI’s E&T projects can boost their careers.
 - View the agenda for the IMI theme in the DIA EuroMeeting programme(page 46)

PharmaTrain success – 12 universities, 1 degree!
November 2012 - IMI project PharmaTrain has successfully launched the Cooperative European Medicines Development Course (CEMDC), a postgraduate qualification in###medicines development. At a ceremony in Budapest, Hungary on 30 October, high-level representatives of 10 universities signed a Memorandum of Understanding formalising the cooperation, which will allow students to take modules offered jointly by the partner universities. Degrees will be formally awarded by Budapest’s Semmelweis University on behalf of the partner universities. The CEMDC was set up by PharmaTrain to provide a university network that could provide pharmaceutical medicine training in countries where no such education was established. The universities involved in the CEMDC are located in Estonia, Hungary, Lithuania, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, and Turkey. The initiative therefore gives students from the central and Eastern European and Mediterranean regions the opportunity to benefit from the very best teaching offered jointly by all participating universities. The university network concept was developed because in small countries and countries with small pharmaceutical industries, only a network concept can guarantee long-lasting sustainability of the programme. The course will start in April 2013. ‘This is a quite unique cooperation which could only be organised within the IMI programme and with the active support of the PharmaTrain cooperation,’ commented CEMDC Study Director Sandor Kerpel-Fronius of Semmelweis University.

Check out the IMI Education & Training projects’ video
November 2012 - Four of IMI’s Education & Training projects have put together a short video on their activities.###In the six-minute clip, the coordinators of the EMTRAIN, SafeSciMET, Eu2P, and PharmaTrain projects present their courses and the benefits they offer for students and course providers alike. The film also features a presentation by IMI Executive Director Michel Goldman.

PharmaTrain goes global
July 2012 - IMI Education and Training project PharmaTrain is extending its global reach by signing Memoranda of Understanding (MoUs) with universities around the world. ###‘Affiliated institutions benefit from the Quality Standards of IMI PharmaTrain and share the interest to find a common process to train medicines development for integrated drug developers and to foster continuing professional development,’ explains PharmaTrain coordinator Fritz Bühler of the University of Basel. The move also allows PharmaTrain to benefit from non-European expertise in medicines training, and also highlights Europe’s leading role in this area. The universities of California and Peking were the first to sign MoUs with PharmaTrain, and the project is in discussions with a number of other institutions. ‘Eventually, one global training concept for medicines development and regulation will emerge which greatly facilitates global medicines development,’ comments Professor Bühler.

All aboard the Pharmatrain!
October 2011 - Hibernia College Dublin in Ireland has been named as the first PharmaTrain Centre of Excellence. ### The college, 1 of 14 training providing partners in the IMI Education & Training project PharmaTrain, used the PharmaTrain Shared Standards to create a new online Master of Medicines Development programme. The announcement means that PharmaTrain is making great strides towards its goal of creating a pan-European, collaborative network for comprehensive post-graduate training. The modular courses devised by the partners allow students to mix and match to tailor their education to their own professional training needs. The project’s short and snappy ‘Career Driver’ newsletter provides regular updates on this successful project’s progress, along with lively quotes from both students and project partners. To sign up, visit the PharmaTrain website.

PharmaTrain is launching new and upgraded Europe-wide Education and Training programmes on Integrated Drug Development Sciences in Autumn 2010.
October 2010 - The programme includes Base courses and Master programmes taught at partner universities all across Europe. ### A full overview is available at www.pharmatrain.eu . Another early achievement of the PharmaTrain project is the publication of a 2010 European Training Syllabus for Pharmaceutical Medicine on the PharmaTrain website . It summarises the learning content that will be addressed in the courses mentioned above. The syllabus has been internationally recognised and adopted by the International Federation of Associations of Pharmaceutical Physicians (IFAPP) and the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom. In Spring 2011, the corresponding detailed learning outcomes will be published in the 'PharmaTrain Programme Handbook. Shared Curriculum and best practices'.

Participants Show participants on map

EFPIA companies
  • Amgen NV, Brussels, Belgium
  • AstraZeneca AB, Södertälje, Sweden
  • Bayer AG, Berlin, Germany
  • F. Hoffmann-La Roche Ltd, Basel, Switzerland
  • Glaxosmithkline Research And Development LTD, Brentford, Middlesex, United Kingdom
  • Janssen Pharmaceutica NV, Beerse, Belgium
  • Laboratorios Almirall S.A., Barcelona, Spain
  • Laboratorios del Dr Esteve, S.A., Barcelona, Spain
  • Merck KGaA, Darmstadt, Germany
  • Novartis Pharma AG, Basel, Switzerland
  • Novo Nordisk A/S, Bagsvaerd, Denmark
  • Orion Corporation, Espoo, Finland
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Sanofi-Aventis Research and Development, Chilly Mazarin, France
  • UCB Biopharma SPRL, Brussels, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Cardiff University, Cardiff, United Kingdom
  • DIA Europe GmbH, Basel, Switzerland
  • European Federation for Pharmaceutical Sciences, Järfälla, Stockholm, Sweden
  • European Forum for Good Clinical Practice, Brussels, Belgium
  • European Organisation for Research and Treatment of Cancer, Brussels, Belgium
  • Faculty of Medicine University of Belgrade, Belgrade, Serbia
  • Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom, London, United Kingdom
  • Goeteborgs Universitet, Gothenburg, Sweden
  • Health Sciences e-Training Foundation, Lausanne, Switzerland
  • Hibernia College, Dublin, Ireland
  • International Federation of Associations of Pharmaceutical Physicians, Woerden, Netherlands
  • Karolinska University Hospital, Stockholm, Sweden
  • King's College London, London, United Kingdom
  • Københavns Universitet (University of Copenhagen), Copenhagen, Denmark
  • Medicines and Healthcare products Regulatory Agency, London, United Kingdom
  • PHARMED asbi, Brussels, Belgium
  • PME Institute for Education in Pharmaceutical Medicine, Witten, Germany
  • PharmaTrain Federation, Basel, Switzerland
  • Semmelweis University, Budapest, Hungary
  • Swissmedic, Berne, Switzerland
  • The Provost, Fellows, Foundation Scholars and the other members of Board, of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin, Dublin, Ireland
  • The University of Surrey, Guildford, United Kingdom
  • Universitaet Basel, Basel, Switzerland
  • Universitaetsklinikum Essen , Essen, Germany
  • Universitaetsklinikum Freiburg, Freiburg, Germany
  • Universitat Autònoma de Barcelona, Bellaterra, Spain
  • Universitat Pompeu Fabra, Barcelona, Spain
  • Universite Claude Bernard Lyon 1, Villeurbanne, France
  • Universite Louis Pasteur, Strasbourg, France
  • Università Cattolica del Sacro Cuore, Milan, Italy
  • Universität Wien, Vienna, Austria
  • Universität de Barcelona, Barcelona, Spain
  • Univesity of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom
Small and medium-sized enterprises (SMEs)
  • Stichting Lygature, Utrecht, Netherlands

CONTACT

Project coordinator
Susanne Daniel
PharmaTrain Federation
susanne.daniel[at]unibas.ch
Managing entity
Susanne Daniel
Universitaet Basel
susanne.daniel[at]unibas.ch